QUIDDITAS

📍 liège, Belgium🗓 Founded 2022👥 6 employees💰 Last funded 2024
Biotechnology Research
LinkedIn
Genome editing-based therapies become the predominant technology of the 21st century with promising statements about genetic diseases treatments. Genome editing tools recently emerged but they suffer from an absence of standardization and their applications remain limited. In this context, Quidditas developed a novel genome editing platform which permits an absolute genetic recombination. Compatible with a larger scope of applications, from bioprocess improvement to genetic disorders treatment, this revolutionary technique will have a major impact in the synthetic Bio field. So “Let’s cure from the beginning!”
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
France
1
United Kingdom
1
Frequently asked questions
Who invested in QUIDDITAS?
QUIDDITAS has 2 investors on record on gritt.io, including 2 early-stage backers.
When did QUIDDITAS last raise funding?
The most recent investment in QUIDDITAS recorded on gritt.io was in 2024.
When was QUIDDITAS founded?
QUIDDITAS was founded in 2022.
What industry is QUIDDITAS in?
QUIDDITAS operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is QUIDDITAS based?
QUIDDITAS is headquartered in liège, Belgium.